Events

Below is a list of events where CELT researchers and staff are presenting CELT research, or events that CELT is endorsing.

A flyer that says

University of Cape Town Department of Medicine annual research symposium

8-9 October 2025, Cape Town South Africa

This year's symposium marks 50 years of excellent research from UCT's Department of Medicine. Dr Marcia Vermeulen has been selected for an oral presentation of the community engagement research carried out for the LONGEVITY project's tuberculosis work.

The presentation is titled 'Patient and provider preferences for long-acting tuberculosis preventive therapy'.

Find out more, including how to register on the symposium event page.

The event title is at the top with pictures of Prajith Venkatasubramanian and Leena Zino with event times underneath them.

Webinar - Innovative drug delivery systems: Lessons for generic manufacturers

9 October 2025, online webinar

This webinar will be an in-depth session designed for generic companies eager to step into the world of complex generics.

It will cover:

Fundamentals of innovative delivery systems
Regulatory pathways & challenges
Key insights to strengthen your competitive edge

Please register via the webinar event page.

An image of Cape Town coast line with text to the left saying:

INHSU 2025: International Conference on Health and Hepatatis in Substance Users

14-17 October 2025, CapeTown South Africa

This year's conference around health and hepatitis in substance users that meaningfully involves people who use drugs is back in its home city for the first time in five years. Shatyam Issur, a LONGEVITY project LAT CAB member, will be presenting a talk on some exciting community engagement research from LONGEVITY.

The presentation title is 'Preferences and feasibility of long-acting technologies for the treatment of hepatitis C virus: A survey of patients in diverse low- and middle-income countries'.

For more information including booking, please head to the INHSU 2025 conference page.

CELT's Community of Practice for long-acting therapeutics for maternal and paediatric health

22 October 2025, online webinar

Community of Practice context

Significant gaps currently exist in the development of new medicines for women of child-bearing age and children, compared with the general adult population. This gap could expand further with new treatment modalities like long-acting therapeutics. Additionally, the extent of breastfed infant exposure through breast milk is largely unknown.

The overarching aim of this community of practice (funded by global health agency Unitaid) is to catalyse the development and availability of long-acting therapeutics of value for maternal and paediatric health globally, including in low- and middle- income countries.

This will be achieved through the following specific objectives:

Engaging relevant stakeholders in academia, clinical practice, pharmaceutical industry, regulators, women and patient groups
Synthesise evidence-based perspectives on best practices for long-acting therapeutics
Disseminate outputs from the community of practice for uptake by the wider community.

The next Community of Practice webinar

The next online session will be held on Wednesday 22 October, 2025, and is titled 'Considerations for Long-acting Injectable Microsuspension Development - Lessons From an Anti-malarial Therapy. V2'. The guest speaker is Laxman Cherkupally, Associate Director – Pharmaceutical Development at Medicines for Malaria Venture (MMV). Laxman will share insights into considerations for long-acting injectables microsuspension development with lessons from an anti-malarial therapy.

You can register to attend virtually on the webinar's Teams link.

To join the Community of Practice and attend this meeting, please fill in this Expression of Interest form to receive an invite link.

We will use this Events page to keep you updated on the remaining events, so please check back. New members are welcome to join the Community of Practice at any point.

a magnifying glass lays on top of papers over the text

Khayelitsha and Eastern Substructure (KESS) Research day

31 October 2025, University of the Western Cape South Africa

This research day aims to create a dynamic and inclusive forum that bridges public health practice, academic research, and community engagement; reinforcing the two institutions’ shared dedication to research excellence and health equity.

The University of Cape Town's Dr Marcia Vermeulen is presenting a 15 minute talk about LONGEVITY tuberculosis community engagement the Dr Vermeulen oversaw. The talk is titled 'Patient and provider preferences for long-acting tuberculosis preventive therapy'.

Find out more, including how to register on the research day event page.

Securing the future: Shaping the UK strategy on long-acting therapeutics

10am-4pm (GMT), 6 November 2025, Liverpool UK

HALo is dedicated to advancing a national strategy that recognises the economic and healthcare potential of long-acting therapeutics in the UK. We aim to accelerate long-acting therapeutics by tackling key technical challenges, engaging patients, raising awareness across clinical and public groups, and establishing a national manufacturing strategy - from pre-clinical proof-of-concept to UK-wide GMP manufacturing - while creating a regulatory environment that supports rapid clinical evaluation and market access.

This event will bring together stakeholders from across the long-acting therapeutics landscape to explore current barriers and opportunities in manufacturing and adoption of LA medicines.

Confirmed speakers include representatives from:

HALo
The NHS (on patient and clinician adoption)
GSK (on their experience in an approved long-acting therapy, cabenuva)
Upperton (a leading CDMO)
Regulatory experts to ensure a well-rounded and forward-looking discussion.

Your insights would be invaluable to this conversation, and we would be delighted to have you, or a member of your team join us.

Contact the HALo team to register or for further information.

AAPS 2025 PHarmSCi 360

9-12 November 2025, San Antonio USA

This four day conference is organised around six core areas; Discovery and basic research; Preclinical, clinical and translational sciences; Bioanalytics; Manufacturing and analytical characterization; Formulation and delivery; Professional advancement track.

CELT Co-Director, Professor Steve Rannard, will be presenting a talk titled 'Injectable nanosuspensions enabling long-acting delivery of small molecules and prodrugs'.

Five CELT members are also presenting posters at the conference:

Sam Galbraith - 'Polymer coated solid injectable dispersions for long-acting delivery of tenofovir alafenamide'
Dr James Hobson - 'Development of long-acting injectable formulations of next generation diarylquinolines for preventive therapy of tuberculosis infection'
Dr Cameron Hogarth - ‘Preclinical development of a long-acting injectable formulation of rifapentine from high throughput screening through to a GLP-toxicology study’
Dr Sam Morris - 'Control of particle size, distribution and modality of a rifapentine solid drug nanoparticle formulation through modified formulation approaches'
Dr Catherine Unsworth - ‘Preclinical development of long-acting injectable formulations of glecaprevir and pibrentasvir for curative treatment of Hepatitis C in low- and middle-income countries’

Find out more, including how to register, on the PHarmSCi 360 event page.

Previous events

LEAP | New Approaches to Bioequivalence Assessment and Generic Approvals for Long Acting/Extended Release Antiretroviral Formulations

Find all the recordings from the workshop talks here.

LEAP | Long-acting Tuberculosis Drug Development Workshop 2024 - 15 April 2024

Watch CELT co-Director Prof. Andrew Owen's presentation here.

Find all the recordings from the workshop here.

19th Residential Course on Clinical Pharmacology and Antiretrovirals - 17-19 January 2024

Download the presentation decks here